Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retlirafusp alfa plus chemotherapy in advanced gastric or GEJ cancer
NCT04950322Phase 3Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Dec 2021
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of retlirafusp alfa in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Started Dec 2021; status: active, not recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04950322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950322.